Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
HCT provides a significant survival benefit for patients with MDS aged 50 to 75, with no negative impacts on quality of life
Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
Abatacept is a promising tool to expand access to HCT, significantly improves survival in 7-8 MMUD HCT
MUD outcomes are superior to haploidentical HCT for lymphoma in an apples-to-apples comparison
Access to and outcomes of HCT for adult underserved populations have improved over time, but African American and other pediatric patients still experience a significant disparity
Study shows mismatched unrelated donor (MMUD) HCT using PTCY and bone marrow is safe and effective
Use of MMUDs can expand HCT access for ethnically diverse populations.
Rapid donor identification improves survival in high-risk first-remission patients with Acute Myeloid Leukemia
John M. Pagel, MD, PhD, Megan Othus, PhD, et al – Barriers to human leukocyte antigen (HLA) typing and cytogenetic testing can significantly impact the overall survival of patients newly diagnosed with acute myeloid leukemia (AML). In this landmark study, a concerted effort to address those issues and streamline the initiation of donor identification and referral for hematopoietic cell transplant (HCT) consultation in early disease state led to a higher CR1 transplantation rate and improved 2-year overall survival.
Auletta J, et al., Transplantation and Cellular Therapy—A manuscript published in Transplantation and Cellular Therapy offered the first report on the impact of the COVID-19 pandemic on the ability of the National Marrow Donor Program® (NMDP)/Be The Match® and the Network to safely deliver unrelated donor products early in the pandemic. The authors found that the NMDP/Be The Match and Network partners continued to effectively deliver domestic and unrelated donor products to allogeneic transplant patients in similar or shorter timeframes than before COVID-19, despite the many unexpected challenges brought about by the pandemic.
Nakamura, R et al., ASH oral abstract presentation, December 2020—Patients ages 65 and older with MDS who received an allogeneic hematopoietic cell transplantation (alloHCT) saw a similar benefit to overall survival (OS) as younger patients (50-64) when compared to other treatments.
Age not a barrier for successful HCT for AML
Updated evidence-based guidelines for optimal selection of unrelated donors and cord blood units for HCT
Dehn J, et al., Blood – A panel of immunogeneticists and other experts in the field of hematopoietic cell transplantation (HCT) has published updated evidence-based guidelines for the optimal selection of unrelated donors and cord blood units used for transplants.
The updated guidelines make recommendations for both HLA and non-HLA factors to consider in graft selection, including donor availability, donor age, patient sensitivity to HLA antigens, natural killer (NK) cell alloreactivity, and minimum total nucleated cell doses and CD34+ cell doses for cord blood units.
Comparable long-term outcomes in matched unrelated and sibling donor HCT in older patients with AML
Shimoni A, et al., Biol Blood Marrow Transplant – In an analysis of 1134 patients age 50 or older with acute myeloid leukemia (AML), two-year hematopoietic cell transplant (HCT) survivors experienced comparable 10-year leukemia-free survival (LFS) and overall survival (OS) with matched sibling or unre-lated donors.
Cappelli B, et al. Haematologica – The youngest of three age-based patient cohorts (age 0-5 years) in a study of 736 patients with sickle cell disease (SCD) undergoing HLA-identical sibling hematopoietic cell transplantation (HCT) experienced 4-year event-free survival of 93%, results the researchers characterized as “excellent.”
Bolaños-Meade J, et al., The Lancet Haematology – In a prospective, phase II trial, researchers found that tacrolimus, mycophenolate mofetil, with post-hematopoietic cell transplant (HCT) cyclophosphamide (TMMCy) produced the best GVHD-free, relapse-free survival (GRFS) for patients who received an allogeneic HCT when compared to the current standard of care.
Subscribe to E-News
Receive new research summaries monthly.